By ONN Staff

FDA approves pivekimab sunirine-pvzy for adults with BPDCN, offering a new CD123-directed therapy for this ultra-rare hematologic malignancy.

A study presented at ONS 2026 shows how primary palliative care interventions improve patient-provider relationships and goal-setting in cellular therapy.

The FDA approved T-DXd for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, showing improved pCR and IDFS rates.

Cedars-Sinai used a nursing education framework to shift a 63-bed oncology unit to a progressive care model, improving immunotherapy monitoring.

A quality improvement project at Sylvester Comprehensive Cancer Center shows that structured education enhances nurse triage for treatment toxicities.

FDA approves atezolizumab and a companion diagnostic for adjuvant treatment of MIBC in patients with detected circulating tumor DNA after surgery.

Hackensack researchers evaluated an antineoplastic agent onboarding program for nurses treating solid and hematologic tumors.

A UAMS study shows non-musical sound machines significantly reduce patient anxiety during gynecology oncology appointments in a cost-effective way.

The FDA approved oral decitabine/cedazuridine and venetoclax for AML. Research showed a 41.6% complete remission rate in chemo-ineligible adults

The FDA approved sonrotoclax for R/R mantle cell lymphoma. Nurses must manage a 4-week dose ramp-up to prevent TLS for patients after prior BTK therapy.

A new survey reveals 53% of rural cancer patients struggle with costs, highlighting urgent needs for patient navigation and policy reform.

Alembic Pharmaceuticals receives FDA approval for Methotrexate Injection for patients with cancer.

The OPTIMAL trial shows oral DHP107 matches IV paclitaxel efficacy in HER2-negative metastatic breast cancer with lower rates of neuropathy.

Each month, Oncology Nursing News® takes a look back at our most popular stories.

Each month, Oncology Nursing News® takes a look back at our most popular stories.

Each month, Oncology Nursing News® takes a look back at our most popular stories.

Each month, Oncology Nursing News® takes a look back at our most popular stories.

Each month, Oncology Nursing News® takes a look back at our most popular stories.

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from October 2022.

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from September 2022.

On September 22 and 23, 2022, the FDA’s Oncologic Drugs Advisory Committee (ODAC) convened for a hearing to assess the risk-benefit ratio of 3 agents.

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from August 2022.

In the modern era, the number of patients with diffuse large B-cell lymphoma who will derive benefit from autologous stem cell transplantation is small, according to Jeremy S. Abramson, MD, MMSc.

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from July 2022.

Phase 3 findings from the POLARIX trial showed that the addition of platuzumab vedotin to rituximab, cyclophosphamide, doxorubicin, and prednisone resulted in a 27% reduction in risk of disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.

A combined analysis of 3 real-world studies assessing the use of ixazomib/lenalidomide/dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma found the patient outcomes to be consistent with original phase 3 findings.

Patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, achieved superior progression-free survival with zanubrutinib vs a combination of bendamustine plus rituximab.

PARP inhibitors emerge as frontline treatment in metastatic castration-resistant prostate cancer, immunotherapy combinations improve quality of life in advanced renal cell carcinoma, and antibody drug conjugates show promise in cisplatin-ineligible urothelial cancer.

Ivosidenib maintains quality of life in cholangiocarcinoma, immunotherapy outperforms chemotherapy in select gastric/gastroesophageal junction adenocarcinoma, and nivolumab induces high response rates are observed among patients with BRAF V600E–mutant metastatic colorectal cancer.

Hennessy spent his career turning his passion for building businesses and creating jobs into a run of successful ventures and brands.